Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1895)	4/2/2003 2:31:37 PM
From: keokalani'nui	Respond to of 2243

AMEV: I might have some of this not quite right.... proprietary programs (preclinical): 1. Optimized Remicade, P1 or IND this year 2. Optimized rituxin, next after remicade 3. BCHE, has a $1m NIH grant for validation in animals (cocaine tox or dependency?). 4. Undisclosed, could take the wraps off 2003 Partnered (burn paid for by partner, mid-single royalty) 1. Medi you know about, Vitaxin and numax (potential multile P2 and P1 2003, per MEDI) 2. Lilly, has earned 2 optimization milestones on Mabs (10/02 and 3/03), working on a protein therapeutic still. 3. Chiron, optimized a non-Mab protein therapeutic, milestone paid 12/02--all in 9 mos. 4. Centocor, started 5/02. 5. CancerVax, optimized 2 contract not extended for remaining 2. 6. BMY, first client. 2 contracts for optimization, completed. BR96 optimized into hBR96, now preclinical with sgen (good luck), and optimized anti-CD-40 Mab still preclinical. 7. Novasite subidiary, created to prove amev can similarly optimize small molecules. Forgotten the large pharma partner, but parent funds 0 burn so they say.(Edit: I see from Tuck's message it is aventis.) cash = market cap = 3 years' burn. This Jim Breitmyer fellow, CMO, looks very competent for a tiny little biotech like amev.